面向患者的药物基因组学工具对给药决策与治疗结局的影响
本研究开发了面向肿瘤患者的YourPGx Oncology门户,以33种患者友好摘要呈现CYP2D6、UGT1A1、DPYD多基因PGx结果。在PhOCus研究(NCT04541381)中,51例患者完成单次观察性评估,用药效识别率从32%升至72%(OR=5.8,P<0.001),毒性识别率从31%升至57%(OR=3.2,P=0.01)。
要点
- 患者使用门户的中位时间为13.4分钟(范围8.1-21.0)。
- 用药效识别准确率从32%升至72%(OR=5.8,P<0.001)。
- 毒性识别准确率从31%升至57%(OR=3.2,P=0.01)。
核心结论
- 定制化患者端PGx结果门户可提升患者对个体化药物疗效与毒性可能性的理解。
研究设计与样本
- 在PhOCus研究(NCT04541381)中开展前瞻性单次观察性评估,190例合格患者中51例(73%)完成会话与前后问卷。
主要发现
- 患者使用门户的中位时间为13.4分钟(范围8.1-21.0)。
- 用药效识别准确率从32%升至72%(OR=5.8,P<0.001)。
- 毒性识别准确率从31%升至57%(OR=3.2,P=0.01)。
临床怎么用
- 药师可借助患者端PGx门户,在患者查看自身CYP2D6、UGT1A1、DPYD结果时提供答疑,促进基因指导的共同决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Germline pharmacogenetics (PGx) is increasingly used to tailor medication selection/dosing. However, existing systems primarily communicate PGx results to providers, limiting direct patient engagement. To address this, we developed YourPGx Oncology, an innovative patient-facing portal that delivers multi-gene PGx results (CYP2D6, UGT1A1, DPYD) through 33 unique, patient-friendly summaries. The utility of this tool was prospectively evaluated in an oncology population, where these pharmacogenes impact high-stakes treatments. Patients enrolled in the PhOCus study (NCT04541381) participated in single-session evaluations of the tool in-person or via videoconference, with a pharmacist available for questions and administering pre- and post-surveys that assessed educational impact. Each patient viewed their own previously obtained PGx results. Of 190 eligible patients, 70 responded to solicitations via email, phone, and in-person, of whom 51 (73%) completed an observed session and completed surveys. Patients spent a median of 13.4 minutes (range 8.1-21.0) navigating YourPGx Oncology. After portal interaction, patients' ability to identify individual efficacy and safety estimates for chemotherapies and pain medications significantly improved, with the proportion accurately recognizing PGx-informed drug efficacy likelihoods rising from 32% to 72% (Odds Ratio [OR] = 5.8 for the shift from discordant to concordant efficacy knowledge, P < 0.001), and PGx-related toxicity recognition increasing from 31% to 57% (OR = 3.2, P = 0.01). Our findings show that a customized patient-facing PGx results portal enhances patient understanding of individual medication efficacy and toxicity likelihoods, highlighting the potential key role of direct-to-patient PGx tools to facilitate optimized treatment-informed care and promote genetically guided shared decision-making.
引用
- Cho Y, Elahi S, Jack MM, et al. Impact of First-of-Its-Kind Patient-Facing Pharmacogenetics Tool on Dosing Decisions and Treatment Outcomes. Clin Pharmacol Ther. 2025. PMID: 40579854. doi:10.1002/cpt.3747
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。